Patent ID: 6864251

Claim:
A method of treating an individual afflicted with an inflammatory disorder mediated by LTB 4 comprising administering to said individual an effective amount of at least one compound according to Formula I: wherein: R 1 is —(C 1 -C 7 )hydrocarbyl or —(C 2 -C 6 )heteroalkyl; R 2 is selected from the group consisting of —H, and —(C 1 -C 7 )hydro-carbyl; wherein R 1 and R 2 may combine to form a carbocyclic or heterocyclic 5- or 6-membered ring; R 3 is independently selected from the group consisting of —O(C 1 -C 6 )alkyl, —OH, —O-acyl, —SH, —S(C 1 -C 3 )alkyl, —NH 2 , —NH(C 1 -C 6 )alkyl, —N((C 1 -C 6 )alkyl) 2 , —NH-acyl, —NO 2 and halogen; n is 1, 2 or 3; R 4 and R 5 are independently selected from the group consisting of —O(C 1 -C 6 )alkyl, —OH, O-acyl, —SH, —S(C 1 -C 3 )alkyl, —NH 2 , NH-acyl and halogen; wherein, R 4 and R 5 may combine to form a 5, 6 or 7-membered heterocyclic ring; and wherein, compounds according to formula I are (R)-enantiomers substantially free of the corresponding (S)-enantiomers, with respect to the absolute conformation at the 5-position of the benzodiazepine ring; or a pharmaceutically-acceptable salt of such a compound.